BioGeometry Raises $100 Million to Scale AI Models That Design Drugs From Scratch
On average, it takes about 10-15 years to produce a new drug. Artificial intelligence could rewrite how new drugs are discovered as BioGeometry raises $100 million. The Beijing-based startup closed The post BioGeometry Raises $100 Million to Scale AI Models That Design Drugs From Scratch appeared first on Ventureburn .
BioGeometry, a Beijing-based AI startup, secured a $100 million investment to accelerate its work in developing AI models capable of designing drugs from scratch. The significant Series A+ extension culminated in a total of Series A funding surpassing $100 million. China Life Capital led the latest round, with support from other investors including Shanghai Biomedical Industry Fund, China Development Venture Capital, Reliance Investment, Guofang Venture Capital, Dacheng Wealth Capital, and Index Capital.
The company's dual AI engines, GeoFlow and GeoCell, work at differing scales to predict biomolecular structures and simulate cell reactions, respectively. With these tools, BioGeometry aims to cut the drug discovery timeline from years to weeks, thereby potentially revolutionizing the drug discovery industry.
Written by urgent.news from Ventureburn's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
